Cargando…

Neoantigens as potential vaccines in hepatocellular carcinoma

BACKGROUND: Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not been invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Repáraz, David, Ruiz, Marta, Llopiz, Diana, Silva, Leyre, Vercher, Enric, Aparicio, Belén, Egea, Josune, Tamayo-Uria, Ibon, Hervás-Stubbs, Sandra, García-Balduz, Jorge, Castro, Carla, Iñarrairaegui, Mercedes, Tagliamonte, Maria, Mauriello, Angela, Cavalluzzo, Beatrice, Buonaguro, Luigi, Rohrer, Charlotte, Heim, Kathrin, Tauber, Catrin, Hofmann, Maike, Thimme, Robert, Sangro, Bruno, Sarobe, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066373/
https://www.ncbi.nlm.nih.gov/pubmed/35193931
http://dx.doi.org/10.1136/jitc-2021-003978
_version_ 1784699790142996480
author Repáraz, David
Ruiz, Marta
Llopiz, Diana
Silva, Leyre
Vercher, Enric
Aparicio, Belén
Egea, Josune
Tamayo-Uria, Ibon
Hervás-Stubbs, Sandra
García-Balduz, Jorge
Castro, Carla
Iñarrairaegui, Mercedes
Tagliamonte, Maria
Mauriello, Angela
Cavalluzzo, Beatrice
Buonaguro, Luigi
Rohrer, Charlotte
Heim, Kathrin
Tauber, Catrin
Hofmann, Maike
Thimme, Robert
Sangro, Bruno
Sarobe, Pablo
author_facet Repáraz, David
Ruiz, Marta
Llopiz, Diana
Silva, Leyre
Vercher, Enric
Aparicio, Belén
Egea, Josune
Tamayo-Uria, Ibon
Hervás-Stubbs, Sandra
García-Balduz, Jorge
Castro, Carla
Iñarrairaegui, Mercedes
Tagliamonte, Maria
Mauriello, Angela
Cavalluzzo, Beatrice
Buonaguro, Luigi
Rohrer, Charlotte
Heim, Kathrin
Tauber, Catrin
Hofmann, Maike
Thimme, Robert
Sangro, Bruno
Sarobe, Pablo
author_sort Repáraz, David
collection PubMed
description BACKGROUND: Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not been investigated. Our aim was to analyze whether tumors in HCC patients contain immunogenic neoantigens suitable for future use in therapeutic vaccination. METHODS: Whole-exome sequencing and RNAseq were performed in a cohort of fourteen HCC patients submitted to surgery or liver transplant. To identify mutations, single-nucleotide variants (SNV) originating non-synonymous changes that were confirmed at the RNA level were analyzed. Immunogenicity of putative neoAgs predicted by HLA binding algorithms was confirmed by using in vitro HLA binding assays and T-cell stimulation experiments, the latter in vivo, by immunizing HLA-A*02.01/HLA-DRB1*01 (HHD-DR1) transgenic mice, and in in vitro, using human lymphocytes. RESULTS: Sequencing led to the identification of a median of 1217 missense somatic SNV per patient, narrowed to 30 when filtering by using RNAseq data. A median of 13 and 5 peptides per patient were predicted as potential binders to HLA class I and class II molecules, respectively. Considering only HLA-A*02.01- and HLA-DRB1*01-predicted binders, 70% demonstrated HLA-binding capacity and about 50% were immunogenic when tested in HHD-DR1 mice. These peptides induced polyfunctional T cells that specifically recognized the mutated but not the wild-type sequence as well as neoantigen-expressing cells. Moreover, coimmunization experiments combining CD8 and CD4 neoantigen epitopes resulted in stronger CD8 T cell responses. Finally, responses against neoantigens were also induced in vitro using human cells. CONCLUSION: These results show that mutations in HCC tumors may generate immunogenic neoantigens with potential applicability for future combinatorial therapeutic strategies.
format Online
Article
Text
id pubmed-9066373
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90663732022-05-12 Neoantigens as potential vaccines in hepatocellular carcinoma Repáraz, David Ruiz, Marta Llopiz, Diana Silva, Leyre Vercher, Enric Aparicio, Belén Egea, Josune Tamayo-Uria, Ibon Hervás-Stubbs, Sandra García-Balduz, Jorge Castro, Carla Iñarrairaegui, Mercedes Tagliamonte, Maria Mauriello, Angela Cavalluzzo, Beatrice Buonaguro, Luigi Rohrer, Charlotte Heim, Kathrin Tauber, Catrin Hofmann, Maike Thimme, Robert Sangro, Bruno Sarobe, Pablo J Immunother Cancer Basic Tumor Immunology BACKGROUND: Neoantigens, new immunogenic sequences arising from tumor mutations, have been associated with response to immunotherapy and are considered potential targets for vaccination. Hepatocellular carcinoma (HCC) is a moderately mutated tumor, where the neoantigen repertoire has not been investigated. Our aim was to analyze whether tumors in HCC patients contain immunogenic neoantigens suitable for future use in therapeutic vaccination. METHODS: Whole-exome sequencing and RNAseq were performed in a cohort of fourteen HCC patients submitted to surgery or liver transplant. To identify mutations, single-nucleotide variants (SNV) originating non-synonymous changes that were confirmed at the RNA level were analyzed. Immunogenicity of putative neoAgs predicted by HLA binding algorithms was confirmed by using in vitro HLA binding assays and T-cell stimulation experiments, the latter in vivo, by immunizing HLA-A*02.01/HLA-DRB1*01 (HHD-DR1) transgenic mice, and in in vitro, using human lymphocytes. RESULTS: Sequencing led to the identification of a median of 1217 missense somatic SNV per patient, narrowed to 30 when filtering by using RNAseq data. A median of 13 and 5 peptides per patient were predicted as potential binders to HLA class I and class II molecules, respectively. Considering only HLA-A*02.01- and HLA-DRB1*01-predicted binders, 70% demonstrated HLA-binding capacity and about 50% were immunogenic when tested in HHD-DR1 mice. These peptides induced polyfunctional T cells that specifically recognized the mutated but not the wild-type sequence as well as neoantigen-expressing cells. Moreover, coimmunization experiments combining CD8 and CD4 neoantigen epitopes resulted in stronger CD8 T cell responses. Finally, responses against neoantigens were also induced in vitro using human cells. CONCLUSION: These results show that mutations in HCC tumors may generate immunogenic neoantigens with potential applicability for future combinatorial therapeutic strategies. BMJ Publishing Group 2022-02-22 /pmc/articles/PMC9066373/ /pubmed/35193931 http://dx.doi.org/10.1136/jitc-2021-003978 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Basic Tumor Immunology
Repáraz, David
Ruiz, Marta
Llopiz, Diana
Silva, Leyre
Vercher, Enric
Aparicio, Belén
Egea, Josune
Tamayo-Uria, Ibon
Hervás-Stubbs, Sandra
García-Balduz, Jorge
Castro, Carla
Iñarrairaegui, Mercedes
Tagliamonte, Maria
Mauriello, Angela
Cavalluzzo, Beatrice
Buonaguro, Luigi
Rohrer, Charlotte
Heim, Kathrin
Tauber, Catrin
Hofmann, Maike
Thimme, Robert
Sangro, Bruno
Sarobe, Pablo
Neoantigens as potential vaccines in hepatocellular carcinoma
title Neoantigens as potential vaccines in hepatocellular carcinoma
title_full Neoantigens as potential vaccines in hepatocellular carcinoma
title_fullStr Neoantigens as potential vaccines in hepatocellular carcinoma
title_full_unstemmed Neoantigens as potential vaccines in hepatocellular carcinoma
title_short Neoantigens as potential vaccines in hepatocellular carcinoma
title_sort neoantigens as potential vaccines in hepatocellular carcinoma
topic Basic Tumor Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066373/
https://www.ncbi.nlm.nih.gov/pubmed/35193931
http://dx.doi.org/10.1136/jitc-2021-003978
work_keys_str_mv AT reparazdavid neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT ruizmarta neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT llopizdiana neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT silvaleyre neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT vercherenric neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT apariciobelen neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT egeajosune neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT tamayouriaibon neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT hervasstubbssandra neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT garciabalduzjorge neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT castrocarla neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT inarrairaeguimercedes neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT tagliamontemaria neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT maurielloangela neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT cavalluzzobeatrice neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT buonaguroluigi neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT rohrercharlotte neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT heimkathrin neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT taubercatrin neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT hofmannmaike neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT thimmerobert neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT sangrobruno neoantigensaspotentialvaccinesinhepatocellularcarcinoma
AT sarobepablo neoantigensaspotentialvaccinesinhepatocellularcarcinoma